journal article·2026-06-11Open access

FOS3D: A Fluorescence‐Enabled Toolkit for Characterizing a Three‐dimensional Osteosarcoma Model

William Humble, Wiktor Zywicki, Enrico Lucarelli, Ania Naila Guerrieri, Francesca Taraballi, Gianluca Cidonio, Claudia Di Bella, Carmine Onofrillo, Andrea J. O'Connor, Serena Duchi

Abstract

ABSTRACT Osteosarcoma (OS) remains a rare, aggressive primary bone malignancy for which therapeutic progress has been limited for several decades. Three‐dimensional (3D) tissue‐engineered models can better reproduce the tumor microenvironment than monolayer cultures; however, their routine use is often constrained by low‐throughput workflows and reliance on destructive analytical endpoints. Here, we present FOS3D, a fluorescence‐enabled OS model based on gelatin methacryloyl hydrogels incorporating stable green fluorescent protein (GFP)‐expressing tumor cells. By varying polymer concentration and photo‐crosslinking duration, hydrogels spanning compressive moduli of approximately 5–50 kPa were generated, covering stiffness ranges reported for OS stromal environments. Whole‐well fluorescence scanning enabled rapid, non‐destructive quantification of proliferation in intact constructs and showed correlation with DNA and metabolic assays. Integration with light‐sheet microscopy further enabled volumetric imaging of tumor organization, revealing time‐dependent changes in spatial distribution. Transcriptional profiling and immunohistochemistry confirmed microenvironment‐driven adaptations associated with extracellular matrix remodeling, stemness, and drug‐resistance pathways. Finally, GFP‐based longitudinal monitoring enabled chemotherapeutic screening of cisplatin and doxorubicin across two OS cell lines, capturing dose‐dependent responses and the increased treatment tolerance characteristic of 3D cultures. Collectively, FOS3D provides a scalable fluorescence‐enabled toolkit for high‐content characterization and drug‐response profiling of OS in physiologically relevant 3D environments.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · 3D Printing in Biomedical Research · Cellular Mechanics and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Aikenhead Centre for Medical Discovery (ACMD) St Vincent's Hospital Melbourne Fitzroy Victoria Australia

Department of Surgery The University of Melbourne St Vincent's Hospital Melbourne Fitzroy Victoria Australia

Department of Biomedical Engineering The Graeme Clark Institute The University of Melbourne Parkville Victoria Australia

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit IRCCS Istituto Ortopedico Rizzoli Bologna Italy

Center For Musculoskeletal Regeneration Houston Methodist Research Institute Houston Texas USA

Orthopaedics and Sports Medicine Houston Methodist Hospital Houston Texas USA

Department of Mechanical and Aerospace Engineering University of Rome La Sapienza Rome Italy

Center For Life Nano‐ & Neuro‐ Science‐CLN2S Italian Institute of Technology (IIT) Rome Italy

Department of Orthopaedics Sarcoma Unit St Vincent's Hospital Melbourne Fitzroy Victoria Australia

References (87)

Show source-provided references
1. 10.1007/s00441‐012‐1441‐510.1007/s00441‐012‐1441‐5 ↗
2. 10.1038/nrc308010.1038/nrc3080 ↗
3. 10.1007/s00253‐014‐6253‐y10.1007/s00253‐014‐6253‐y ↗
4. 10.1016/j.biopha.2025.11847110.1016/j.biopha.2025.118471 ↗
5. 10.3389/fonc.2018.0000410.3389/fonc.2018.00004 ↗
6. 10.1089/ten.TEB.2020.025410.1089/ten.TEB.2020.0254 ↗
7. 10.1038/nbt.278610.1038/nbt.2786 ↗
8. 10.3390/genes1404083210.3390/genes14040832 ↗
9. 10.1038/s41572‐022‐00409‐y10.1038/s41572‐022‐00409‐y ↗
10. 10.3892/ol.2019.1122910.3892/ol.2019.11229 ↗
11. 10.1002/gcc.2071710.1002/gcc.20717 ↗
12. 10.3389/fonc.2020.0001310.3389/fonc.2020.00013 ↗
13. 10.1016/j.canlet.2017.07.02410.1016/j.canlet.2017.07.024 ↗
14. Tumor Blood Vessels Formation in Osteosarcoma: Vasculogenesis Mimicry
15. 10.1038/labinvest.2011.7210.1038/labinvest.2011.72 ↗
16. 10.2215/CJN.0415120610.2215/CJN.04151206 ↗
17. 10.1146/annurev‐bioeng‐071516‐04461910.1146/annurev‐bioeng‐071516‐044619 ↗
18. 10.4172/2157‐7552.100017310.4172/2157‐7552.1000173 ↗
19. 10.1177/108705711769679510.1177/1087057117696795 ↗
20. 10.1016/j.mtchem.2024.10211110.1016/j.mtchem.2024.102111 ↗
21. 10.3390/bioengineering503005510.3390/bioengineering5030055 ↗
22. 10.1039/c7sm02187a10.1039/c7sm02187a ↗
23. 10.1016/j.jmbbm.2015.06.02310.1016/j.jmbbm.2015.06.023 ↗
24. 10.1089/ten.2005.11.18210.1089/ten.2005.11.182 ↗
25. 10.1186/s12929‐024‐00994‐y10.1186/s12929‐024‐00994‐y ↗
26. 10.1016/s1470‐2045(02)00848‐310.1016/s1470‐2045(02)00848‐3 ↗
27. 10.1186/s13104‐020‐4914‐810.1186/s13104‐020‐4914‐8 ↗
28. 10.5603/FHC.2013.002710.5603/FHC.2013.0027 ↗
29. 10.1016/s0042‐6989(01)00237‐110.1016/s0042‐6989(01)00237‐1 ↗
30. 10.1007/s10585‐009‐9259‐610.1007/s10585‐009‐9259‐6 ↗
31. 10.1002/jcb.2560310.1002/jcb.25603 ↗
32. 10.1002/adfm.20231594010.1002/adfm.202315940 ↗
33. 10.20455/ros.2016.87310.20455/ros.2016.873 ↗
34. May P‐Glycoprotein Status be Used to Stratify High‐Grade Osteosarcoma Patients? Results From the Italian/Scandinavian Sarcoma Group 1 Treatment Protocol
35. 10.3892/ijo.14.2.30110.3892/ijo.14.2.301 ↗
36. 10.1158/1078‐0432.CCR‐25‐064910.1158/1078‐0432.CCR‐25‐0649 ↗
37. 10.1038/labinvest.2014.15410.1038/labinvest.2014.154 ↗
38. 10.1096/fj.04‐3180fje10.1096/fj.04‐3180fje ↗
39. 10.1186/s13046‐020‐01548‐410.1186/s13046‐020‐01548‐4 ↗
40. 10.1098/rsif.2016.064910.1098/rsif.2016.0649 ↗
41. 10.1038/nrc383810.1038/nrc3838 ↗
42. 10.1093/annonc/mdq27610.1093/annonc/mdq276 ↗
43. 10.1086/62429810.1086/624298 ↗
44. 10.18103/mra.v8i7.217010.18103/mra.v8i7.2170 ↗
45. 10.1155/2013/93625410.1155/2013/936254 ↗
46. 10.7860/JCDR/2016/18181.812610.7860/JCDR/2016/18181.8126 ↗
47. 10.1016/s0959‐8049(97)00341‐910.1016/s0959‐8049(97)00341‐9 ↗
48. 10.1007/s00280‐023‐04637‐110.1007/s00280‐023‐04637‐1 ↗
49. 10.3390/cancers1401019010.3390/cancers14010190 ↗
50. 10.1039/d3ma00715d10.1039/d3ma00715d ↗
51. 10.1016/j.ijbiomac.2023.12639110.1016/j.ijbiomac.2023.126391 ↗
52. 10.1089/ten.TEB.2023.010610.1089/ten.TEB.2023.0106 ↗
53. 10.1016/j.biomaterials.2017.02.01510.1016/j.biomaterials.2017.02.015 ↗
54. Dahlin J. L. · 2004
55. 10.1242/jcs.03971910.1242/jcs.039719 ↗
56. 10.1038/nrc131710.1038/nrc1317 ↗
57. 10.1038/s41392‐024‐01891‐410.1038/s41392‐024‐01891‐4 ↗
58. 10.1083/jcb.20230714310.1083/jcb.202307143 ↗
59. 10.1016/j.actbio.2019.07.01110.1016/j.actbio.2019.07.011 ↗
60. 10.1039/c9bm02075f10.1039/c9bm02075f ↗
61. 10.1387/ijdb.190019us10.1387/ijdb.190019us ↗
62. 10.1016/j.ijsu.2015.04.05010.1016/j.ijsu.2015.04.050 ↗
63. 10.1053/hupa.2001.2352410.1053/hupa.2001.23524 ↗
64. 10.1038/cddiscovery.2017.3610.1038/cddiscovery.2017.36 ↗
65. 10.1038/s41401‐025‐01650‐310.1038/s41401‐025‐01650‐3 ↗
66. 10.1016/j.prp.2023.15432910.1016/j.prp.2023.154329 ↗
67. 10.1155/2011/28274510.1155/2011/282745 ↗
68. 10.1002/jbmr.157410.1002/jbmr.1574 ↗
69. 10.3892/ol.2015.403510.3892/ol.2015.4035 ↗
70. 10.1038/s41419‐024‐06487‐y10.1038/s41419‐024‐06487‐y ↗
71. 10.7150/jca.7233110.7150/jca.72331 ↗
72. 10.3892/ijo.2016.350910.3892/ijo.2016.3509 ↗
73. 10.3109/13880209.2013.77264010.3109/13880209.2013.772640 ↗
74. 10.1016/j.msec.2019.11026410.1016/j.msec.2019.110264 ↗
75. 10.1002/term.180010.1002/term.1800 ↗
76. 10.3390/cancers1601016410.3390/cancers16010164 ↗
77. 10.1038/s41420‐021‐00658‐y10.1038/s41420‐021‐00658‐y ↗
78. 10.1089/dna.2006.053110.1089/dna.2006.0531 ↗
79. 10.1016/j.isci.2024.11025110.1016/j.isci.2024.110251 ↗
80. 10.1002/adhm.20220076810.1002/adhm.202200768 ↗
81. 10.1073/pnas.200117811710.1073/pnas.2001178117 ↗
82. 10.1016/j.biopha.2025.11895610.1016/j.biopha.2025.118956 ↗
83. 10.2147/IJN.S11170110.2147/IJN.S111701 ↗
84. 10.1016/j.bioactmat.2024.04.03210.1016/j.bioactmat.2024.04.032 ↗
85. 10.3390/ijms1911367010.3390/ijms19113670 ↗
86. 10.1086/62404010.1086/624040 ↗
87. 10.1251/bpo11410.1251/bpo114 ↗